{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:39:16Z","timestamp":1794310756062,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001111"],"award-info":[{"award-number":["UL1TR001111"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12012-017-9425-z","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T05:36:16Z","timestamp":1504157776000},"page":"487-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism"],"prefix":"10.1007","volume":"17","author":[{"given":"Mary","family":"Banks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6430-8344","authenticated-orcid":false,"given":"Brian C.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"9425_CR1","first-page":"2251","volume":"8","author":"I Lugowska","year":"2015","unstructured":"Lugowska, I., Kosela-Paterczyk, H., Kozak, K., & Rutkowski, P. (2015). Trametinib: A MEK inhibitor for management of metastatic melanoma. OncoTargets and Therapy, \n                           8, 2251\u20132259.","journal-title":"OncoTargets and Therapy"},{"key":"9425_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","volume":"11","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y., & Adjei, A. A. (2014). The clinical development of MEK inhibitors. Nature Reviews Clinical Oncology, \n                           11, 385\u2013400.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"9425_CR3","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.ejca.2013.03.020","volume":"49","author":"JR Infante","year":"2013","unstructured":"Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., 3rd, Rasco, D., et al. (2013). A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer, \n                           49, 2077\u20132085.","journal-title":"European Journal of Cancer"},{"key":"9425_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1158\/1535-7163.MCT-15-0170","volume":"15","author":"VL Bridgeman","year":"2016","unstructured":"Bridgeman, V. L., Wan, E., Foo, S., Nathan, M. R., Welti, J. C., Frentzas, S., et al. (2016). Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma. Molecular Cancer Therapeutics, \n                           15, 172\u2013183.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"9425_CR5","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.cllc.2016.11.001","volume":"18","author":"LM Pervere","year":"2017","unstructured":"Pervere, L. M., Rakshit, S., Schrock, A. B., Miller, V. A., Ali, S. M., Velcheti, V. (2017). Durable response to combination of dabrafenib and trametinib in BRAF V600E-mutated non-small-cell lung cancer. Clinical Lung Cancer, \n                           18(3), e211\u2013e213.","journal-title":"Clinical Lung Cancer"},{"key":"9425_CR6","doi-asserted-by":"crossref","unstructured":"Cho, H., Matsumoto, S., Fujita, Y., Kuroda, A., Menju, T., Sonobe, M., et al. (2017). Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-l1 in malignant pleural mesothelioma. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, \n                           12(3), 477\u2013490.","DOI":"10.1016\/j.jtho.2016.10.023"},{"key":"9425_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","volume":"417","author":"R Roskoski Jr","year":"2012","unstructured":"Roskoski, R., Jr. (2012). MEK1\/2 dual-specificity protein kinases: Structure and regulation. Biochemical and Biophysical Research Communications, \n                           417, 5\u201310.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"9425_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, \n                           17, 989\u20131000.","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"9425_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England Journal of Medicine, \n                           367, 107\u2013114.","journal-title":"The New England Journal of Medicine"},{"key":"9425_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, \n                           417, 949\u2013954.","journal-title":"Nature"},{"key":"9425_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, \n                           439, 358\u2013362.","journal-title":"Nature"},{"key":"9425_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England Journal of Medicine, \n                           372, 30\u201339.","journal-title":"The New England Journal of Medicine"},{"key":"9425_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet, \n                           386, 444\u2013451.","journal-title":"Lancet"},{"key":"9425_CR14","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1097\/MPH.0000000000000364","volume":"37","author":"S Modak","year":"2015","unstructured":"Modak, S., Asante-Korang, A., Steinherz, L. J., & Grana, N. (2015). Trametinib-induced left ventricular dysfunction in a child with relapsed neuroblastoma. Journal of Pediatric Hematology\/oncology, \n                           37, e381\u2013e383.","journal-title":"Journal of Pediatric Hematology\/oncology"},{"key":"9425_CR15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1634\/theoncologist.2016-0080","volume":"21","author":"D Tseng","year":"2016","unstructured":"Tseng, D., Mason, X. L., Neilan, T. G., & Sullivan, R. J. (2016). Cardiogenic shock and respiratory failure in a patient with metastatic melanoma receiving trametinib therapy. The Oncologist, \n                           21, 1136\u20131137.","journal-title":"The Oncologist"},{"key":"9425_CR16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","volume":"13","author":"GS Falchook","year":"2012","unstructured":"Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. The Lancet Oncology, \n                           13, 782\u2013789.","journal-title":"The Lancet Oncology"},{"key":"9425_CR17","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","volume":"50","author":"JR Infante","year":"2014","unstructured":"Infante, J. R., Somer, B. G., Park, J. O., Li, C. P., Scheulen, M. E., Kasubhai, S. M., et al. (2014). A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, \n                           50, 2072\u20132081.","journal-title":"European Journal of Cancer"},{"key":"9425_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard, D., Besse, B., Groen, H. J., Souquet, P. J., Quoix, E., Baik, C. S., et al. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. The Lancet Oncology, \n                           17, 984\u2013993.","journal-title":"The Lancet Oncology"},{"key":"9425_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","volume":"31","author":"KB Kim","year":"2013","unstructured":"Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., et al. (2013). Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, \n                           31, 482\u2013489.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"9425_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","volume":"38","author":"RR Shah","year":"2015","unstructured":"Shah, R. R., & Morganroth, J. (2015). Update on cardiovascular safety of tyrosine kinase inhibitors: With a special focus on qt interval, left ventricular dysfunction and overall risk\/benefit. Drug Safety, \n                           38, 693\u2013710.","journal-title":"Drug Safety"},{"key":"9425_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdu482","volume":"26","author":"AW Tolcher","year":"2015","unstructured":"Tolcher, A. W., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., 3rd, Patnaik, A., Jones, S. F., et al. (2015). A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology, \n                           26, 58\u201364.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"11","key":"9425_CR22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/bjc.2017.119","volume":"116","author":"RT Shroff","year":"2017","unstructured":"Shroff, R. T., Yarchoan, M., O\u2019Connor, A., Gallagher, D., Zahurak, M. L., Rosner, G., et al. (2017). The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. British Journal of Cancer, \n                           116(11), 1402\u20131407.","journal-title":"British Journal of Cancer"},{"key":"9425_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00280-014-2615-5","volume":"75","author":"AW Tolcher","year":"2015","unstructured":"Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., et al. (2015). Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemotherapy and Pharmacology, \n                           75, 183\u2013189.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9425_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/bjc.2014.564","volume":"112","author":"P Ghatalia","year":"2015","unstructured":"Ghatalia, P., Je, Y., Kaymakcalan, M. D., Sonpavde, G., & Choueiri, T. K. (2015). QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. British Journal of Cancer, \n                           112, 296\u2013305.","journal-title":"British Journal of Cancer"},{"key":"9425_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00280-016-3090-y","volume":"78","author":"A Patnaik","year":"2016","unstructured":"Patnaik, A., Tolcher, A., Papadopoulos, K. P., Beeram, M., Rasco, D., Werner, T. L., et al. (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Cancer Chemotherapy and Pharmacology, \n                           78, 491\u2013500.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9425_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cardfail.2013.12.018","volume":"20","author":"A Thakur","year":"2014","unstructured":"Thakur, A., & Witteles, R. M. (2014). Cancer therapy-induced left ventricular dysfunction: Interventions and prognosis. Journal of Cardiac Failure, \n                           20, 155\u2013158.","journal-title":"Journal of Cardiac Failure"},{"key":"9425_CR27","doi-asserted-by":"publisher","first-page":"26295","DOI":"10.1074\/jbc.M212352200","volume":"278","author":"LA Hu","year":"2003","unstructured":"Hu, L. A., Chen, W., Martin, N. P., Whalen, E. J., Premont, R. T., & Lefkowitz, R. J. (2003). Gipc interacts with the \u03b21-adrenergic receptor and regulates \u03b21-adrenergic receptor-mediated ERK activation. The Journal of Biological Chemistry, \n                           278, 26295\u201326301.","journal-title":"The Journal of Biological Chemistry"},{"key":"9425_CR28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/01.RES.86.10.1047","volume":"86","author":"A Sabri","year":"2000","unstructured":"Sabri, A., Pak, E., Alcott, S. A., Wilson, B. A., & Steinberg, S. F. (2000). Coupling function of endogenous \u03b1(1)- and \u03b2-adrenergic receptors in mouse cardiomyocytes. Circulation Research, \n                           86, 1047\u20131053.","journal-title":"Circulation Research"},{"key":"9425_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.yjmcc.2010.10.021","volume":"51","author":"MS Marber","year":"2011","unstructured":"Marber, M. S., Rose, B., & Wang, Y. (2011). The p38 mitogen-activated protein kinase pathway\u2014a potential target for intervention in infarction, hypertrophy, and heart failure. Journal of Molecular and Cellular Cardiology, \n                           51, 485\u2013490.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9425_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacc.2006.05.005","volume":"48","author":"R Kerkela","year":"2006","unstructured":"Kerkela, R., & Force, T. (2006). P38 mitogen-activated protein kinase: A future target for heart failure therapy? Journal of the American College of Cardiology, \n                           48, 556\u2013558.","journal-title":"Journal of the American College of Cardiology"},{"key":"9425_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00395-007-0658-z","volume":"102","author":"P Fischer","year":"2007","unstructured":"Fischer, P., & Hilfiker-Kleiner, D. (2007). Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Research in Cardiology, \n                           102, 279\u2013297.","journal-title":"Basic Research in Cardiology"},{"key":"9425_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","volume":"90","author":"BA Rose","year":"2010","unstructured":"Rose, B. A., Force, T., & Wang, Y. (2010). Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiological Reviews, \n                           90, 1507\u20131546.","journal-title":"Physiological Reviews"},{"key":"9425_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1172\/JCI119709","volume":"100","author":"R Aikawa","year":"1997","unstructured":"Aikawa, R., Komuro, I., Yamazaki, T., Zou, Y., Kudoh, S., Tanaka, M., et al. (1997). Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. The Journal of Clinical Investigation, \n                           100, 1813\u20131821.","journal-title":"The Journal of Clinical Investigation"},{"key":"9425_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.RES.0000038488.38975.1A","volume":"91","author":"OF Bueno","year":"2002","unstructured":"Bueno, O. F., & Molkentin, J. D. (2002). Involvement of extracellular signal-regulated kinases 1\/2 in cardiac hypertrophy and cell death. Circulation Research, \n                           91, 776\u2013781.","journal-title":"Circulation Research"},{"key":"9425_CR35","doi-asserted-by":"publisher","first-page":"H1925","DOI":"10.1152\/ajpheart.01054.2004","volume":"288","author":"H Lou","year":"2005","unstructured":"Lou, H., Danelisen, I., & Singal, P. K. (2005). Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. American Journal of Physiology Heart and Circulatory Physiology, \n                           288, H1925\u2013H1930.","journal-title":"American Journal of Physiology Heart and Circulatory Physiology"},{"key":"9425_CR36","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.CIR.0000127126.73759.23","volume":"109","author":"DJ Lips","year":"2004","unstructured":"Lips, D. J., Bueno, O. F., Wilkins, B. J., Purcell, N. H., Kaiser, R. A., Lorenz, J. N., et al. (2004). MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation, \n                           109, 1938\u20131941.","journal-title":"Circulation"},{"key":"9425_CR37","doi-asserted-by":"publisher","first-page":"14074","DOI":"10.1073\/pnas.0610906104","volume":"104","author":"NH Purcell","year":"2007","unstructured":"Purcell, N. H., Wilkins, B. J., York, A., Saba-El-Leil, M. K., Meloche, S., Robbins, J., et al. (2007). Genetic inhibition of cardiac ERK1\/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proceedings of the National Academy of Sciences of the United States of America, \n                           104, 14074\u201314079.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9425_CR38","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/CIRCRESAHA.114.303200","volume":"114","author":"JM Duran","year":"2014","unstructured":"Duran, J. M., Makarewich, C. A., Trappanese, D., Gross, P., Husain, S., Dunn, J., et al. (2014). Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circulation Research, \n                           114, 1700\u20131712.","journal-title":"Circulation Research"},{"key":"9425_CR39","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","volume":"31","author":"M Chavez-MacGregor","year":"2013","unstructured":"Chavez-MacGregor, M., Zhang, N., Buchholz, T. A., Zhang, Y., Niu, J., Elting, L., et al. (2013). Trastuzumab-related cardiotoxicity among older patients with breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, \n                           31, 4222\u20134228.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-017-9425-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-017-9425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-017-9425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:51:41Z","timestamp":1589723501000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-017-9425-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["9425"],"URL":"https:\/\/doi.org\/10.1007\/s12012-017-9425-z","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]},"assertion":[{"value":"31 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}